Hemophilia A is an X-linked bleeding disorder caused by deficiency of coagulation factor VIII (FVIII), with severity classified as severe (<1% FVIII activity), moderate (1–5%), or mild (>5%). [1-2] The cornerstone of emergency management is immediate factor VIII replacement based on clinical suspicion of bleeding, before diagnostic confirmation. [3-4]
1. History
- Bleed location and onset: Joint (hemarthrosis — ankles, knees, elbows most common), muscle, mucosal, intracranial, GI, genitourinary [5-6]
- Timing: Spontaneous vs. traumatic; delayed or renewed bleeding after initial hemostasis is characteristic [6]
- Severity classification: Known baseline FVIII level (severe <1%, moderate 1–5%, mild >5%) [1]
- Prophylaxis status: Current regimen (FVIII concentrate, emicizumab, fitusiran, concizumab, marstacimab), last dose, missed doses [6-7]
- Inhibitor history: Known inhibitor status and titer (Bethesda Units); prior response to bypassing agents [1]
- Prior bleeding episodes: Frequency, target joints, prior ICH, prior hospitalizations
- Important negatives: Deny head trauma, deny neck/throat swelling, deny abdominal pain, deny hematuria
2. Alarm Features
- Intracranial hemorrhage — headache, vomiting, altered mental status, seizures, focal neurologic deficits; leading cause of death in hemophilia [5-6]
- Neck/throat/airway bleeding — potential airway compromise
- Iliopsoas hemorrhage — groin/hip pain, hip flexion posture, femoral neuropathy (39% of cases develop femoral nerve compression) [8-9]
- Compartment syndrome — pain out of proportion, pain on passive stretch, tense compartment; requires fasciotomy if limb perfusion pressure <30 mmHg [10-11]
- Retroperitoneal hemorrhage — flank/abdominal pain, hemodynamic instability [3]
- GI hemorrhage — hematemesis, melena, hemodynamic compromise
- Any head trauma in a known hemophiliac — treat first, image second [3-4]
3. Medications
Factor VIII Replacement (primary treatment)
- Dosing formula: Required IU = body weight (kg) × desired FVIII rise (%) × 0.5 [12]
- 1 IU/kg raises FVIII activity by ~2 IU/dL [12]
For patients with inhibitors
- Low-titer (<5 BU): Higher doses of FVIII may overcome the inhibitor [1][5]
- High-titer (≥5 BU): Bypassing agents — rFVIIa (NovoSeven) 90 µg/kg q2–3h or APCC (FEIBA) 50–100 U/kg (max 200 U/kg/day) [1][5][13]
- Patients on emicizumab: Use rFVIIa for breakthrough bleeds; avoid APCC due to thrombotic microangiopathy risk [14-15]
Desmopressin (DDAVP)
- For mild hemophilia A (FVIII >5%) without inhibitors: 0.3 µg/kg IV over 15–30 min; raises FVIII 2–6× baseline [1][16-17]
- Tachyphylaxis occurs with dosing more frequently than q48h [16]
- Restrict fluids to <1.5 L/day to prevent hyponatremia; avoid in children <3 years [1]
Adjunctive agents
- Tranexamic acid (TXA): 10–15 mg/kg IV or 25 mg/kg PO q6–8h for mucosal bleeding (oral, nasal, GI, menorrhagia) [1]
- Contraindicated in upper urinary tract (renal) bleeding — risk of obstructive clot [1]
Contraindicated medications
- Aspirin and NSAIDs — impair platelet function and worsen bleeding [6][18]
- Intramuscular injections without factor coverage [6]
- Cryoprecipitate and FFP are not recommended for hemophilia A [4]
4. Diet
- No specific dietary triggers for acute bleeding crisis
- Fluid restriction (<1.5 L/day) is essential when using desmopressin to prevent hyponatremia [1]
- Long-term: Adequate calcium and vitamin D for bone health given risk of hemophilic arthropathy and reduced weight-bearing activity
- Avoid excessive alcohol (hepatotoxicity risk, impaired coagulation)
5. Review of Systems
- Neurologic: Headache, vision changes, altered consciousness, seizures (ICH)
- Musculoskeletal: Joint pain/swelling, limited ROM, limping, muscle tightness
- GI: Abdominal pain, hematemesis, melena, hematochezia
- GU: Hematuria (common; usually self-limited but may indicate renal bleed)
- Skin: Bruising pattern, subcutaneous hematomas
- ENT: Epistaxis, oral mucosal bleeding, throat/neck swelling
6. Collateral History and Family History
- X-linked inheritance: Maternal carrier status, affected male relatives; ~30% are de novo mutations with no family history [1]
- Patient's hemophilia treatment center (HTC) records: Baseline FVIII level, inhibitor status, specific factor product used, treatment plan
- Medical alert bracelet/card: Many patients carry factor product and treatment plans [4]
- Use patient-supplied factor products when available — maximizes treatment speed and safety [4]
7. Risk Factors
- Severe disease (FVIII <1%): 2–5 spontaneous bleeds/month without prophylaxis [6]
- Non-adherence to prophylaxis: Missed doses significantly increase bleed risk [8]
- Inhibitor development: Occurs in 30–50% of severe hemophilia A patients; dramatically increases morbidity [1-2]
- High-risk activities: Contact sports, activities with head injury risk [6]
- Surgical/dental procedures without factor coverage
- Age: Increased joint bleeding with age (21% of bleeds in ages 1–6 → 60% in adults) [5]
8. Differential Diagnosis
- Hemophilia B (factor IX deficiency) — clinically indistinguishable; differentiated by specific factor assays [1]
- Von Willebrand disease (especially type 2N) — low FVIII due to impaired VWF-FVIII binding; check VWF antigen/activity [1]
- Acquired hemophilia A — autoantibodies to FVIII; typically older adults, postpartum, autoimmune conditions; mixing study does not correct [19]
- Other rare factor deficiencies (FXI, FV, combined FV/FVIII) [19-20]
- Non-accidental trauma — must be considered in pediatric patients with unexplained bruising [6]
- Platelet function disorders — normal PT/aPTT with mucocutaneous bleeding pattern [19]
9. Past Medical History
- Known severity classification and baseline FVIII level
- Target joints — joints with recurrent hemarthrosis and established arthropathy
- Prior inhibitor development and immune tolerance induction (ITI) history [1][21]
- Transfusion-related infections (HIV, HCV — historical risk with plasma-derived products) [22]
- Prior surgeries — especially joint replacements, port placements
- Current prophylactic regimen — FVIII concentrate, emicizumab, fitusiran, concizumab, or marstacimab [6-7]
10. Physical Exam
- Vitals: Tachycardia and hypotension suggest significant hemorrhage
- Neurologic: GCS, pupil reactivity, focal deficits (ICH screening)
- Joints: Warmth, swelling, effusion, limited ROM — compare to baseline; ankles, knees, elbows most affected [5]
- Muscles: Tense/firm compartments, pain on passive stretch (compartment syndrome); hip flexion posture with femoral nerve palsy (iliopsoas bleed) [8][11]
- Abdomen: Tenderness, guarding, flank ecchymosis (retroperitoneal bleed)
- Oropharynx/neck: Floor-of-mouth hematoma, sublingual swelling (airway threat)
- Skin: Distribution and character of bruising — firm subcutaneous hematomas are characteristic [6]
11. Lab Studies
- aPTT: Prolonged (screening test; correlates with FVIII deficiency) [1]
- PT/INR: Normal [1]
- Platelet count: Normal [6]
- Factor VIII activity level: Confirms diagnosis and guides dosing; obtain pre- and post-infusion levels [1]
- Inhibitor screen (Bethesda assay): Essential if suboptimal response to factor replacement; obtain if not recently checked [1][6]
- CBC: Assess for anemia from blood loss
- Type and screen: For significant hemorrhage
- BMP: Baseline; monitor sodium if using desmopressin [1]
- Fibrinogen, D-dimer: If DIC is a concern
12. Imaging
- Head CT without contrast: Immediate for any head trauma or neurologic symptoms — treat with factor FIRST, then image [3-4]
- Ultrasound: First-line for joint effusions and superficial muscle hematomas; can identify iliopsoas hematoma [9]
- CT abdomen/pelvis with contrast: Gold standard for retroperitoneal and iliopsoas hemorrhage [8]
- Joint X-rays: Assess for chronic hemophilic arthropathy; not useful for acute hemarthrosis
- MRI: Best for evaluating chronic joint damage, soft tissue bleeds when clinically stable
- Imaging is unnecessary for uncomplicated minor hemarthrosis in a known hemophiliac responding to factor replacement
13. Special Tests
- Mixing study: Prolonged aPTT that corrects with 1:1 mix = factor deficiency; failure to correct = inhibitor or lupus anticoagulant [1]
- Bethesda assay / Nijmegen modification: Quantifies inhibitor titer in BU [1][23]
- Chromogenic FVIII assay: Detects some mild hemophilia A variants missed by one-stage assay [1]
- Genetic testing: Identifies F8 mutation; predicts severity, inhibitor risk, carrier status [1]
- DDAVP challenge test: Pre-treatment trial to document FVIII response in mild hemophilia A [1][24]
- Compartment pressure measurement: When clinical exam is equivocal; fasciotomy if limb perfusion pressure <30 mmHg [11]
14. ECG
- Not routinely indicated for bleeding crisis
- Obtain if hemodynamically unstable or significant blood loss to evaluate for ischemia or dysrhythmia
- Consider in older hemophilia patients on antithrombotic therapy for cardiovascular comorbidities [25]
15. Assessment
Severity stratification is the critical first step
- Typical presentation: Known hemophiliac with acute joint pain/swelling (hemarthrosis) or muscle hematoma
- Atypical presentations: First presentation in mild hemophilia after surgery; acquired hemophilia in elderly; female carriers with low FVIII [6]
- Complications: Hemophilic arthropathy (leading cause of disability), inhibitor development (most significant treatment complication), compartment syndrome, femoral neuropathy from iliopsoas bleed, pseudotumors [6][9-10]
16. Treatment Plan
Initial stabilization
- ABCs; large-bore IV access; hemodynamic resuscitation as needed
- Administer factor VIII immediately based on clinical suspicion — do not wait for labs or imaging [3-4]
By bleed type
- Life-threatening bleeds (ICH, airway, GI, retroperitoneal): FVIII 50 IU/kg to achieve 100% activity; repeat q8–24h for 10–14 days [1][3][12]
- Hemarthrosis: FVIII 10–20 IU/kg (target 20–40%); RICE protocol; avoid weight-bearing; graduated physiotherapy in recovery [1][12]
- Muscle hematoma: FVIII 15–30 IU/kg (target 30–60%); monitor for compartment syndrome [11-12]
- Mild hemophilia A: Desmopressin 0.3 µg/kg IV if documented responder; restrict fluids [1][16]
- Mucosal bleeding: Add tranexamic acid 10–15 mg/kg IV or 25 mg/kg PO q6–8h [1]
Inhibitor patients
- rFVIIa 90 µg/kg q2–3h or APCC (FEIBA) 50–100 U/kg; max 200 U/kg/day [1][5][13]
- Consult hematology urgently
Analgesia
- Acetaminophen first-line; COX-2 inhibitors with caution; avoid aspirin and traditional NSAIDs [6]
- Opioids for severe pain as needed
17. Disposition
Admit for
- All life-threatening bleeds: ICH, airway, GI, retroperitoneal, iliopsoas [3]
- Compartment syndrome or concern for neurovascular compromise [11]
- Hemodynamic instability or significant blood loss
- Patients with inhibitors and active bleeding
- Inability to administer factor at home
- New diagnosis of hemophilia with active bleeding
Observation
- Moderate muscle bleeds or hemarthrosis not responding to initial factor replacement
- Head trauma with normal CT — observe with serial neuro checks; consider repeat imaging at 24h
Discharge criteria
- Minor hemarthrosis or mucosal bleed responding to factor replacement
- Hemodynamically stable with adequate factor levels
- Reliable home infusion capability and access to factor product
- Clear follow-up plan with HTC or hematology
Consult hematology for all ED presentations; early coordination with the patient's HTC is critical [3][26]
18. Follow Up / Return Precautions
Follow-up timing
- HTC or hematology follow-up within 24–48 hours for any ED visit
- Severe/moderate hemophilia: HTC assessment every 6–12 months [6]
- Mild hemophilia: HTC assessment every 1–2 years [6]
- Inhibitor screening: During first 10–20 treatment days, then q3–6 months, then annually after 50–100 exposure days [6]
Return precautions — instruct to return immediately for
- Headache, vomiting, confusion, vision changes, or any neurologic change
- Increasing pain, swelling, or tightness in a limb (compartment syndrome)
- Groin pain with inability to extend hip (iliopsoas bleed)
- Hematemesis, melena, or signs of significant blood loss
- Bleeding not controlled with home factor infusion
- Fever or signs of infection at port/CVAD site
Patient counseling
- Emphasize adherence to prophylactic regimen — missed doses significantly increase bleed risk [8]
- Avoid aspirin, NSAIDs, and IM injections without factor coverage [6]
- Wear medical alert identification at all times
- Carry factor product and treatment plan when traveling [4]
- Expected recovery: Minor hemarthrosis typically resolves in 1–3 days with treatment; major bleeds may require 10–14 days of factor coverage [1]
Images
References
1. Haemophilia. — Chowdary P, Carcao M, Kenet G, Pipe SW. Lancet. 2025.
2. Non-Clotting Factor Therapies for Preventing Bleeds in People With Congenital Hemophilia a or B. — Olasupo OO, Noronha N, Lowe MS, et al. The Cochrane Database of Systematic Reviews. 2026.
3. High Risk and Low Prevalence Diseases: Hemophilia Emergencies. — Alblaihed L, Dubbs SB, Koyfman A, Long B. The American Journal of Emergency Medicine. 2022.
4. Hematologic Emergencies: Recognition and Initial Management. — Jones DE, Walker JJ, Abellada AMP. American Family Physician. 2024.
5. The Past and Future of Haemophilia: Diagnosis, Treatments, and Its Complications. — Peyvandi F, Garagiola I, Young G. Lancet. 2016.
6. Hemophilia A. — Konkle BA, Nakaya Fletcher S GeneReviews® [Internet]. 2025.
7. FDA Orange Book. — FDA Orange Book. 2026.
8. Emergency Department Presentation of Iliopsoas Hematoma in a Severe Hemophiliac. — Burgess A, Douglas D, Grubish L. The American Journal of Emergency Medicine. 2018.
9. Iliopsoas Haemorrhage Complicated by Femoral Neuropathy in Patients With Haemophilia: A Case Series Report. — Panuwannakorn M, Jiravichitchai T, Lertthammakiat S, et al. International Journal of Hematology. 2023.
10. Orthopedic Surgical Procedures in People With Hemophilia. — Encinas-Ullan CA, De la Corte-Rodriguez H, Gomez-Cardero P, Rodriguez-Merchan EC. Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis. 2023.
11. Acute Compartment Syndrome in Haemophilia. — Rodriguez-Merchan EC. Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis. 2013.
12. FDA Drug Label. — Updated date: 2010-08-31. Food and Drug Administration.
13. FDA Drug Label. — Updated date: 2025-11-27. Food and Drug Administration.
14. Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. — Mancuso ME, Chan AKC, Shanmukhaiah C, et al. The New England Journal of Medicine. 2026.
15. Hematological Treatment and Prophylaxis in Patients With and Without Inhibitors. — Marco-Rico A. Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis. 2023.
16. FDA Drug Label. — Updated date: 2022-10-12. Food and Drug Administration.
17. FDA Drug Label. — Updated date: 2025-10-23. Food and Drug Administration.
18. Blood Coagulation. — Dahlbäck B. Lancet. 2000.
19. Bleeding and Bruising: Primary Care Evaluation. — Hughes PR, Lewis MN, Adams SS. American Family Physician. 2024.
20. Evaluation for Bleeding Disorders in Suspected Child Abuse. — Anderst J, Carpenter SL, Abshire TC, et al. Pediatrics. 2022.
21. Toward Optimal Therapy for Inhibitors in Hemophilia. — Kempton CL, Meeks SL. Blood. 2014.
22. Hemophilia A. — Hoyer LW. The New England Journal of Medicine. 1994.
23. Rituximab for Treating Inhibitors in People With Inherited Severe Hemophilia. — Jiang L, Liu Y, Zhang L, Santoro C, Rodriguez A. The Cochrane Database of Systematic Reviews. 2020.
24. Genotype-Dependent Response to Desmopressin in Hemophilia a and Proposal of a Predictive Response Score. — Guillet B, Pawlowski M, Boisseau P, et al. Thrombosis and Haemostasis. 2024.
25. Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients With Hemophilia: Results From the French Registry. — Guillet B, Cayla G, Lebreton A, et al. Thrombosis and Haemostasis. 2021.
26. Hemophilia and Von Willebrand Disease: A Review of Emergency Department Management. — Tebo C, Gibson C, Mazer-Amirshahi M. The Journal of Emergency Medicine. 2020.